Amid a busy year and new leadership, Lonza looks to build bioconjugates capacity with Swiss expansion set for 2022
The year 2020 has been busy for contract manufacturers, a trend which is holding strong as an unprecedented 12 months draw to a close. Swiss CDMO Lonza, one of the biggest players in the field and under the recent leadership of Roche vet Pierre-Alain Ruffieux, has been at the forefront of that outsourcing boom, and now it’s looking to keep on growing for what could be an even busier future.
Buoyed by deals to produce 1 billion worldwide doses of Moderna’s Covid-19 vaccine, Lonza announced an expansion Monday that will increase its production capacity 30% by the first half of 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
